- Report
- September 2025
- 23 Pages
Germany
From €995EUR$1,217USD£894GBP
- Report
- September 2025
- 24 Pages
South Korea
From €995EUR$1,217USD£894GBP
- Report
- September 2025
- 24 Pages
Mexico
From €995EUR$1,217USD£894GBP
- Report
- September 2025
- 21 Pages
Argentina
From €995EUR$1,217USD£894GBP
- Report
- September 2025
- 28 Pages
Australia
From €995EUR$1,217USD£894GBP
- Report
- September 2025
- 25 Pages
Austria
From €995EUR$1,217USD£894GBP
- Report
- September 2025
- 25 Pages
Austria
From €995EUR$1,217USD£894GBP
- Report
- September 2025
- 28 Pages
Australia
From €995EUR$1,217USD£894GBP
- Report
- September 2025
- 21 Pages
Argentina
From €995EUR$1,217USD£894GBP
- Report
- March 2025
- 193 Pages
China
From €3503EUR$4,000USD£3,041GBP
- Report
- March 2025
- 43 Pages
China
From €1576EUR$1,800USD£1,368GBP
- Report
- October 2024
- 23 Pages
Ukraine
From €995EUR$1,217USD£894GBP
- Report
- October 2024
- 24 Pages
Ukraine
From €995EUR$1,217USD£894GBP
- Report
- October 2024
- 21 Pages
Morocco
From €995EUR$1,217USD£894GBP
- Report
- October 2024
- 21 Pages
Morocco
From €995EUR$1,217USD£894GBP
- Report
- September 2024
- 18 Pages
Vietnam
From €995EUR$1,217USD£894GBP
- Report
- March 2024
- 80 Pages
China
From €1576EUR$1,800USD£1,368GBP
- Book
- May 2025
North America

The AIDS market within the context of Allergy and Immunology is focused on the development of treatments and therapies for HIV/AIDS. This includes the development of drugs to treat HIV infection, as well as vaccines and other therapies to prevent the spread of the virus. Additionally, research is being conducted to better understand the mechanisms of HIV infection and the development of new treatments.
The market is highly competitive, with many companies vying for a share of the market. Companies such as Gilead Sciences, Merck, GlaxoSmithKline, Bristol-Myers Squibb, and ViiV Healthcare are all major players in the AIDS market. Other companies such as AbbVie, Janssen, and Pfizer are also involved in the development of treatments and therapies for HIV/AIDS. Show Less Read more